These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30234161)

  • 1. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.
    Miyake T; Yoshida S; Furukawa S; Sakai T; Tada F; Senba H; Yamamoto S; Koizumi Y; Yoshida O; Hirooka M; Kumagi T; Niiya T; Miyaoka H; Masanori A; Matsuura B; Hiasa Y
    Open Med (Wars); 2018; 13():402-409. PubMed ID: 30234161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
    Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
    Hepatol Res; 2017 Sep; 47(10):1072-1078. PubMed ID: 27925353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial.
    Han E; Lee YH; Lee BW; Kang ES; Cha BS
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31963648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease.
    Pokharel A; Kc S; Thapa P; Karki N; Shrestha R; Jaishi B; Paudel MS
    Cureus; 2021 Jul; 13(7):e16687. PubMed ID: 34466320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
    Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
    Ogawa Y; Nakahara T; Ando Y; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Murakami E; Kawaoka T; Miki D; Yamauchi M; Tsuge M; Imamura M; Oka S
    Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):989-996. PubMed ID: 37395206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on the correlation between type 2 diabetes mellitus combined with non-alcoholic steatohepatitis and aerobic exercise performance].
    Zhang J; Li L; Yu HY; Li Y; Wang FM; Di FS
    Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1068-1074. PubMed ID: 38016772
    [No Abstract]   [Full Text] [Related]  

  • 10. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD.
    Oh S; Tsujimoto T; Kim B; Uchida F; Suzuki H; Iizumi S; Isobe T; Sakae T; Tanaka K; Shoda J
    JHEP Rep; 2021 Jun; 3(3):100253. PubMed ID: 33898958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
    Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Intern Med; 2024 Feb; ():. PubMed ID: 38346734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
    Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
    PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
    Takahashi H; Kessoku T; Kawanaka M; Nonaka M; Hyogo H; Fujii H; Nakajima T; Imajo K; Tanaka K; Kubotsu Y; Isoda H; Oeda S; Kurai O; Yoneda M; Ono M; Kitajima Y; Tajiri R; Takamori A; Kawaguchi A; Aishima S; Kage M; Nakajima A; Eguchi Y; Anzai K
    Hepatol Commun; 2022 Jan; 6(1):120-132. PubMed ID: 34558835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.
    Arai T; Atsukawa M; Tsubota A; Mikami S; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Emoto N; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
    Ther Adv Endocrinol Metab; 2021; 12():20420188211000243. PubMed ID: 33815743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
    Morishita A; Tadokoro T; Fujihara S; Iwama H; Oura K; Fujita K; Tani J; Takuma K; Nakahara M; Shi T; Haba R; Okano K; Nishiyama A; Ono M; Himoto T; Masaki T
    PLoS One; 2022; 17(2):e0261310. PubMed ID: 35192632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Tian F; Zheng Z; Zhang D; He S; Shen J
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.